<DOC>
	<DOCNO>NCT01620307</DOCNO>
	<brief_summary>Severe H1N1 pneumonia acute respiratory failure show hyperactive immune cell infiltration lung . Rapamune , mTOR inhibitor , modulate immune response block activation T- B-cells . To investigate clinical efficiency rapamune severe H1N1 pneumonia respiratory failure , study conduct .</brief_summary>
	<brief_title>Rapamune Improves Outcomes Severe H1N1 Pneumonia</brief_title>
	<detailed_description>From 2009 winter 2011 spring , patient flu-like symptom Chang Gung Memorial Hospital screen rapid antigen test influenza subtype confirm polymerization chain reaction ( PCR ) . 38 H1N1 patient severe hypoxemia [ alveolar-arterial oxygen gradient , ( A-a ) O2 gradient , &gt; 200 mmHg ] require ventilator support randomize receive Rapamune ( 2mg/day ) . Patients randomize receive either Sirolimus ( Rapamune 2mg/day , Pfizer ) course 14 day . The outcome variable include liberation ventilator , ICU mortality , necessity ECMO , Sequential Organ Failure Assessment ( SOFA ) score complication admission ICU record . SOFA score compose score six organ system , grade 0 4 accord degree dysfunction/failure .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>H1N1 patient severe hypoxemia [ alveolararterial oxygen gradient , ( Aa ) O2 gradient , &gt; 200 mmHg ] require ventilator support include randomization . severity illness multiple organ dysfunction ( MOD ) assess within 24 hour ICU admission .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>H1N1 patient severe hypoxemia require ventilator support</keyword>
</DOC>